Publication |
2018
Abstract
The article summarizes the findings regarding the complex involvement of B lymphocytes in the development and maintenance of autoimmune inflammation in MS. Substances that cause B cell depletion are mentioned.
The greatest attention is paid to ocrelizumab, its mechanism of action, the results of clinical trials and adverse effects. Ocrelizumab is the first monoclonal antibody that targets B cells that are significantly involved in the immunopathogenesis of MS.
It is approved for the treatment of patients with relapsing remitting, but also primary, progressive MS. Ocrelizumab is a drug with excellent adherence and a very good benefit/risk ratio.